Eko has announced a collaboration with AstraZeneca to accelerate the development of digital health tools for the earlier screening of cardiovascular diseases, including heart failure.
Through the collaboration, AstraZeneca and Eko will explore accelerating the development of Eko algorithms, enhancing clinical trials with Eko technology and potentially building new heart failure detection solutions.
Joris Silon, senior vice president, Cardiovascular Renal and Metabolism, AstraZeneca, said: “There are millions of people living with or at risk for heart failure. AstraZeneca’s collaboration with Eko will tap into cutting-edge digital health technologies that could allow us to harness the potential to improve access to individualised care and generate better patient outcomes.”
In December 2019, Eko announced US Food and Drug Administration (FDA) Breakthrough Device Designation for a novel ECG-based algorithm that can identify reduced left ventricular ejection fraction (LVEF). This algorithm, when cleared by the FDA, will be compatible with the DUO, Eko’s handheld stethoscope and ECG device.
“Eko was founded to provide a better way to understand our heart and lung health and to improve cardiopulmonary care for patients through digital technology and novel algorithms,” said Connor Landgraf, CEO and co-founder of Eko. “Eko’s collaboration with AstraZeneca will allow us to expand the capability of our technology, generate real-world data, and explore disease management solutions while leveraging AstraZeneca’s global expertise and existing relationships across the treatment continuum for heart failure.”